Reduction of HBV and HDV infection in two indigenous peoples of Peruvian Amazon after the vaccination against hepatitis B

Cabezas C.; Trujillo O.; Balbuena J.; Terrazas M.; Manrique-de Lara C.; Marín L.; Ramírez-Soto M.C. · Salud Publica de Mexico (2020) · DOI: 10.21149/11128

Resumen

Objective. To determine the outcome of the vaccination against hepatitis, we determined the prevalence of hepatitis B virus (HBV) and hepatitis D virus (HDV) infections, eight years after introduction of the vaccination. Materials and methods. A cross-sectional study was performed in 2 944 participants of 67 Kandozi and Chapra indigenous peoples in April 2010. Serological screening for hepatitis B surface antigen (HBsAg), antibody anti-HBc IgM and IgG, antibody anti-HBs and anti-HDV were determined by ELISA tests. Results. The prevalence rates of HBsAg, anti-HBc total, anti-HBs ≥10 mlUI/ml and anti-HDV were 2.3, 39.13, 50.95 and 2.11%, respectively. The prevalence rate of HBsAg in children <11 years was 0%. Among carriers of HBsAg, the prevalence rates of HDV and acute HBV infections were 2.11% (all were >14 years) and 11.94%, respectively. HBsAg and anti-HBc total were associated with individuals ≥10 years (p<0.001). Conclusions. These findings show the elimination of HBV carriers in children <11 years, eight years following introduction of the vaccination against HBV.

Instituciones: Universidad Peruana Cayetano Heredia; Universidad Nacional Mayor de San Marcos; Universidad Nacional Federico Villarreal